Generic pharmaceutical business Amerigen Pharmaceuticals Limited reported on Wednesday the receipt of final approval from the US Food and Drug Administration for the Abbreviated New Drug Application (ANDA) for Penicillamine Capsules USP in 250 mg.
According to the company, Penicillamine Capsules USP are indicated in the treatment of Wilson's disease, cystinuria as well as in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
This is the first ANDA to be approved as a generic equivalent to Bausch Heath's Cuprimine, Amerigen said.
In the US, the Penicillamine Capsules USP in 250 mg has already been launched by the company's affiliate, Amerigen Pharmaceuticals Inc.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins